FDA Issues Warning Letter Over APAPs
The agency cited unapproved modifications to the an auto-CPAP system imported into the United States and a failure to report a firmware correction for unexpected shutdowns.
The agency cited unapproved modifications to the an auto-CPAP system imported into the United States and a failure to report a firmware correction for unexpected shutdowns.
The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.
The prescription-only reusable EPAP device offers two therapeutic back pressure settings to treat obstructive sleep apnea.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
Melatonin – a go-to sleep aid for kids and adults alike in many households in America – continues to create media buzz, with conflicting messages that leave people uncertain about its safety.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.